Portal de Periódicos da CAPES

Treatment of Sickle Cell Anemia with Hydroxyurea and Erythropoietin

1990; Massachusetts Medical Society; Volume: 323; Issue: 6 Linguagem: Inglês

10.1056/nejm199008093230602

1533-4406

Mark A. Goldberg, Carlo Brugnara, George J. Dover, Lidia Schapira, Samuel Charache, H. Franklin Bunn,

Iron Metabolism and Disorders

Hydroxyurea increases the production of fetal hemoglobin (hemoglobin F) in patients with sickle cell anemia and therefore has the potential for alleviating both the hemolytic and vaso-occlusive manifestations of the disease. There is preliminary evidence that recombinant human erythropoietin may also increase hemoglobin F production.